Mucosal Barrier Function In Patients Research Articles

Application of optical medical equipment imaging detection and fire needle therapy for intestinal mucosal barrier function in patients with intestinal diseases

Application of optical medical equipment imaging detection and fire needle therapy for intestinal mucosal barrier function in patients with intestinal diseases

Impact of octreotide combined with omeprazole on gastrointestinal hormones and intestinal mucosal barrier function in patients with acute pancreatitis

Impact of octreotide combined with omeprazole on gastrointestinal hormones and intestinal mucosal barrier function in patients with acute pancreatitis

Effect of eco-enteral nutrition on lymphocyte subsets and intestinal mucosal barrier function in patients with gastrointestinal fistula after gastrointestinal surgery

Effect of eco-enteral nutrition on lymphocyte subsets and intestinal mucosal barrier function in patients with gastrointestinal fistula after gastrointestinal surgery

Effect of glutamine-enriched nutritional support on intestinal mucosal barrier function, MMP-2, MMP-9 and immune function in patients with advanced gastric cancer during perioperative chemotherapy.

We studied the effects of glutamine-enriched nutritional support on intestinal mucosal barrier, matrix metalloproteinase (MMP)-2, MMP-9 and immune function during perioperative chemotherapy in patients with advanced gastric cancer. The study was conducted on 94 patients with advanced gastric cancer admitted from April 2015 to March 2016. They were randomly divided into observation and control groups, n=47. Control group was given basic nutritional support whereas glutamine-enriched nutritional support was given to patients in observation group. High-performance liquid chromatography was used to measure lactulose and mannitol ratio in urine (L/M) and ELISA was used to measure D-lactate levels before chemotherapy and in the 1st, 2nd and 3rd cycle of chemotherapy. Immunoglobulin level was detected by immune turbidimetry assay, T lymphocyte subsets were determined by flow cytometry after 3 cycles of chemotherapy, MMP-2 and MMP-9 of patients were compared between the two groups. The serious adverse reactions incidence (grade and IV) of patients were observed. To evaluate the life quality of patients, QLQ-C30 was used after 6 months. The levels of L/M and D-lactate in both groups after the first cycle of chemotherapy were significantly higher than that before chemotherapy; they began to decline after the second or third cycle, but were still significantly higher than the levels before chemotherapy (p<0.05). On comparison, between the two groups after 1st, 2nd, 3rd cycle after chemotherapy, L/M and D-lactate levels of patients in the observation group were significantly lower than in the control group (p<0.05). Incidence of serious adverse reactions (grades III and IV) in observation group was significantly lower than control group (p<0.05). At follow-up of 6 months, living quality scores of patients in observation group were significantly higher than control group (p<0.05). Glutamine-enriched nutritional support can effectively protect the intestinal mucosal barrier function in patients with advanced gastric cancer in their perioperative chemotherapy, improve the level of MMP-2 and MMP-9 in patients with advanced gastric cancer, enhance their immune function, reduce the incidence of adverse reactions and improve their quality of life, which is of remarkable clinical application value.

Culturing human intestinal stem cells for regenerative applications in the treatment of inflammatory bowel disease.

Both the incidence and prevalence of inflammatory bowel disease (IBD) is increasing globally; in the industrialized world up to 0.5% of the population are affected and around 4.2 million individuals suffer from IBD in Europe and North America combined. Successful engraftment in experimental colitis models suggests that intestinal stem cell transplantation could constitute a novel treatment strategy to re‐establish mucosal barrier function in patients with severe disease. Intestinal stem cells can be grown in vitro in organoid structures, though only a fraction of the cells contained are stem cells with regenerative capabilities. Hence, techniques to enrich stem cell populations are being pursued through the development of multiple two‐dimensional and three‐dimensional culture protocols, as well as co‐culture techniques and multiple growth medium compositions. Moreover, research in support matrices allowing for efficient clinical application is in progress. In vitro culture is accomplished by modulating the signaling pathways fundamental for the stem cell niche with a suitable culture matrix to provide additional contact‐dependent stimuli and structural support. The aim of this review was to discuss medium compositions and support matrices for optimal intestinal stem cell culture, as well as potential modifications to advance clinical use in IBD.

Berberine Reduces Uremia-Associated Intestinal Mucosal Barrier Damage.

Berberine is one of the main active constituents of Rhizoma coptidis, a traditional Chinese medicine, and has long been used for the treatment of gastrointestinal disorders. The present study was designed to investigate the effects of berberine on the intestinal mucosal barrier damage in a rat uremia model induced by the 5/6 kidney resection. Beginning at postoperative week 4, the uremia rats were treated with daily 150 mg/kg berberine by oral gavage for 6 weeks. To assess the intestinal mucosal barrier changes, blood samples were collected for measuring the serum D-lactate level, and terminal ileum tissue samples were used for analyses of intestinal permeability, myeloperoxidase activity, histopathology, malondialdehyde (MDA) level, and superoxide dismutase (SOD) activity. Berberine treatment resulted in significant decreases in the serum D-lactate level, intestinal permeability, intestinal myeloperoxidase activity, and intestinal mucosal and submucosal edema and inflammation, and the Chiu's scores assessed for intestinal mucosal injury. The intestinal MDA level was reduced and the intestinal SOD activity was increased following berberine treatment. In conclusion, berberine reduces intestinal mucosal barrier damage induced by uremia, which is most likely due to its anti-oxidative activity. It may be developed as a potential treatment for preserving intestinal mucosal barrier function in patients with uremia.

Protective effect of periplaneta americana extract on intestinal mucosal barrier function in patients with sepsis

ObjectiveTo investigate the effect of the periplaneta americana extract on the intestinal mucosal barrier and prognostic implications in patients with sepsis. MethodsSixty and six patients with sepsis were assigned randomly to treatment group (32 cases) and control group (32 cases). The extractfrom periplaneta americana plus conventional medication for sepsis was administered to the treatment group, while the control group only received conventional treatment. The gastrointestinal function scores and acute physiology and chronic health evaluation II (APACHE II) scores of all subjects were documented at baseline, at days 1, 3 and 7 after treatment respectively and their blood endotoxin was tested at the same time points as well. The incidence of death was recorded for both groups throughout the trial. ResultsAt days 3 and 7 after treatment, gastrointestinal function score, APACHE II, and endotoxin level in treatment group wasbetter than that in control group and the difference between them was significant (both P 7<0.05). Although the incidence of death in treatment group was less than that in control group, the difference between the two groups was not significant (P > 0.05). ConclusionThe extract of periplaneta americana had protective effect on intestinal mucosal barrier and could improve the condition and prognosis in patients with sepsis.

Dietary fiber in protection of intestinal mucosal barrier in patients with ulcerative colitis

Objective To explore the protective effect of enteral nutrition (EN) containing dietary fiber complex (DFC) in intestinal mucosal barrier function in patients with ulcerative colitis.Methods The patients with ulcerative colitis received sulfasalazine tablets of 1.0 g four times daily for two weeks.Then 90 of the patients whose symptoms did not become severe were randomly divided into three groups.Group C received no-DFC nutrition,while group T1 and T2 separately received EN with soluble dietary fiber or insoluble dietary fiber (every 500 kcal of EN with 7.5 g DFC) in certain proportion of 1 ∶ 3.Before and after a 7-day treatment,plasma concentrations of TNF-α and endotoxin (ET) were detected.Results 7 days after therapy with EN,concentration of TNF-α (144.5 ± 20.0) ng/L in group T1 and (140.6 ± 19.2) ng/L in group T2 was markedly lower than that in group C (170.7 ± 30.4) ng/L (P＜0.05),while the difference between groups T1 and T2 had no statistical significance (P＞0.05).Concentration of ET (0.137 ± 0.018) Eu/ml in group T1 or (0.130 ± 0.017) Eu/ml in group T2 was lower than that in group C (0.156 ± 0.012) Eu/ml (P＜0.05),and there was no statistical difference between groups T1 and T2 (P＞0.05).C onclusions Enteral nutrition containing proper amount of dietary fiber complex can reduce intestinal permeability and protect intestinal mucosal barrier function in patients with ulcerative colitis. Key words: Ulcerative colitis; Mucosal barrier; Dietary fiber; Tumor necrosis factor; Endotoxin

Effect of early enteral nutrition supplemented with glutamine on postoperative intestinal mucosal barrier function in patients with gastric carcinoma

To investigate the effect of early enteral nutrition (EEN) supplemented with glutamine on postoperative intestinal mucosal barrier function of patients with gastric carcinoma. Eighty patients with gastric carcinoma who underwent intraoperative peritoneal hyperthermic chemotherapy(IPHC) were randomized into two groups: EEN+glutamine (EEN+Gln) group(n=40) and EEN group(n=40). Intestinal mucosal barrier function was evaluated by serum diamine oxidase (DAO), ratio of lactulose to mannitol(L/M), endotoxin lipopolysaccharides(LPS), and tumor necrosis factor-α(TNF-α) at 1 day before operation, 1 day, 7 days, 12 days after operation. Time to first flatus and tolerance to EEN were recorded as well. There were no significant differences in the two groups in demographics(all P>0.05). Two cases(5%) in the EEN+Gln group and 1 case (2.5%) in the EEN group could not tolerate well(P>0.05). On postoperative day 1, there were no differences in serum DAO, L/M ratio, LPS, TNF-α between the two groups (P>0.05). On postoperative day 7, all the parameters for mucosal barrier function were significantly lower in the EEN+Gln group. On postoperative day 12, the urinary L/M and DAO, LPS, and TNF-α were still significantly lower in the EEN+Gln group, however, urinary L/M was comparable between the two groups. There were no differences between the two groups in the time to first flatus (P>0.05). The immunologic tolerance of enteral nutrition supplemented with glutamine is favorable, which provides protective effect on intestinal mucosal barrier in patients with gastric carcinoma undergoing IPHC.

Effect of Yiqi Tongfu Zhuyu decoction enema therapy on intestinal mucosal barrier function in patients with sepsis

Effect of Yiqi Tongfu Zhuyu decoction enema therapy on intestinal mucosal barrier function in patients with sepsis

Changes in intestinal mucosal barrier function in patients with liver diseases: effect of glutamine intervention

Changes in intestinal mucosal barrier function in patients with liver diseases: effect of glutamine intervention

Clinical trial: effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhoea‐predominant irritable bowel syndrome

The intestinal permeability is increased in patients with diarrhoea-predominant irritable bowel syndrome (D-IBS). To determine the possible efficacy of lactic acid bacteria on the increased intestinal permeability in D-IBS. Treatment was employed for 4 weeks in a randomized single blind placebo controlled study with 30 D-IBS patients. Patients were given either probiotic fermented milk (Streptococcus thermophilus, Lactobacillus bulgaricus, Lactobacillus acidophilus and Bifidobacterium Longum) or milk beverage containing no bacteria. The clinical symptoms were scored and intestinal permeability was measured by a triple sugar test before and after treatment. Small bowel permeability was measured as the ratio of lactulose and mannitol recovery and colonic permeability was measured as the total mass of sucralose excretion (mg). After probiotics treatment, small bowel permeability decreased significantly from 0.038 (0.024) at baseline to 0.023 (0.020) (P = 0.004), the proportion of patients with increased small bowel permeability was lower than baseline (28.6% vs. 64.3%, P = 0.023). However, colonic permeability improved neither in the probiotics group nor in the placebo group at week 4. Treatment with probiotics significantly decreased the mean global IBS scores compared with the baseline scores (9.62 +/- 1.05 vs. 7.64 +/- 1.24, P < 0.001). Short-term active lactic acid bacteria treatment for D-IBS improved mucosal barrier function.